These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37875924)

  • 1. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle.
    Pacak CA; Suzuki-Hatano S; Khadir F; Daugherty AL; Sriramvenugopal M; Gosiker BJ; Kang PB; Cade WT
    J Transl Med; 2023 Oct; 21(1):748. PubMed ID: 37875924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV-Mediated TAZ Gene Replacement Restores Mitochondrial and Cardioskeletal Function in Barth Syndrome.
    Suzuki-Hatano S; Saha M; Rizzo SA; Witko RL; Gosiker BJ; Ramanathan M; Soustek MS; Jones MD; Kang PB; Byrne BJ; Cade WT; Pacak CA
    Hum Gene Ther; 2019 Feb; 30(2):139-154. PubMed ID: 30070157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cryoprecipitate augments the global transduction of the adeno-associated virus serotype 9 after a systemic administration.
    Chai Z; Zhang X; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2018 Sep; 286():415-424. PubMed ID: 30107215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of heart ischemia and administration route on biodistribution and transduction efficiency of AAV9 vectors.
    García-Olloqui P; Rodriguez-Madoz JR; Di Scala M; Abizanda G; Vales Á; Olagüe C; Iglesias-García O; Larequi E; Aguado-Alvaro LP; Ruiz-Villalba A; Prosper F; Gonzalez-Aseguinolaza G; Pelacho B
    J Tissue Eng Regen Med; 2020 Jan; 14(1):123-134. PubMed ID: 31677236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart.
    Qiao C; Yuan Z; Li J; Tang R; Li J; Xiao X
    Hum Gene Ther Methods; 2012 Feb; 23(1):29-37. PubMed ID: 22428978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration.
    Beharry A; Gong Y; Kim JC; Hanlon KS; Nammour J; Hieber K; Eichler F; Cheng M; Stemmer-Rachamimov A; Stankovic KM; Welling DB; Ng C; Maguire CA
    Hum Gene Ther; 2022 Jan; 33(1-2):61-75. PubMed ID: 34128391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimization of Dexamethasone Administration for Maintaining Global Transduction Efficacy of Adeno-Associated Virus Serotype 9.
    Chai Z; Zhang X; Dobbins AL; Rigsbee KM; Wang B; Samulski RJ; Li C
    Hum Gene Ther; 2019 Jul; 30(7):829-840. PubMed ID: 30700148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuraminidase-mediated desialylation augments AAV9-mediated gene expression in skeletal muscle.
    Zhu H; Wang T; John Lye R; French BA; Annex BH
    J Gene Med; 2018 Sep; 20(9):e3049. PubMed ID: 30101537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adeno-associated virus serotype 9 efficiently targets ischemic skeletal muscle following systemic delivery.
    Katwal AB; Konkalmatt PR; Piras BA; Hazarika S; Li SS; John Lye R; Sanders JM; Ferrante EA; Yan Z; Annex BH; French BA
    Gene Ther; 2013 Sep; 20(9):930-8. PubMed ID: 23535898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo selection in non-human primates identifies AAV capsids for on-target CSF delivery to spinal cord.
    Hanlon KS; Cheng M; Ferrer RM; Ryu JR; Lee B; De La Cruz D; Patel N; Espinoza P; Santoscoy MC; Gong Y; Ng C; Nguyen DM; Nammour J; Clark SW; Heine VM; Sun W; Kozarsky K; Maguire CA
    Mol Ther; 2024 Aug; 32(8):2584-2603. PubMed ID: 38845196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Context-Specific Function of the Engineered Peptide Domain of PHP.B.
    Martino RA; Fluck EC; Murphy J; Wang Q; Hoff H; Pumroy RA; Lee CY; Sims JJ; Roy S; Moiseenkova-Bell VY; Wilson JM
    J Virol; 2021 Sep; 95(20):e0116421. PubMed ID: 34346767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.
    Zhang X; Chai Z; Lee Dobbins A; Itano MS; Askew C; Miao Z; Niu H; Samulski RJ; Li C
    Biomaterials; 2022 Feb; 281():121340. PubMed ID: 34998171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9.
    Saraiva J; Nobre RJ; Pereira de Almeida L
    J Control Release; 2016 Nov; 241():94-109. PubMed ID: 27637390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local and systemic administration of AAV vectors with alphaherpesvirus latency-associated promoter 2 drives potent transgene expression in mouse liver, kidney, and skeletal muscle.
    Maturana CJ; Chan A; Verpeut JL; Engel EA
    J Virol Methods; 2023 Apr; 314():114688. PubMed ID: 36736702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neonatal Systemic AAV-Mediated Gene Delivery of GDF11 Inhibits Skeletal Muscle Growth.
    Jin Q; Qiao C; Li J; Li J; Xiao X
    Mol Ther; 2018 Apr; 26(4):1109-1117. PubMed ID: 29503194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial-Specific Gene Delivery Using an Adeno-Associated Viral Vector.
    Ni L; Scott L; Campbell HM; Pan X; Alsina KM; Reynolds J; Philippen LE; Hulsurkar M; Lagor WR; Li N; Wehrens XHT
    Circ Res; 2019 Jan; 124(2):256-262. PubMed ID: 30582449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.
    Hinderer C; Katz N; Buza EL; Dyer C; Goode T; Bell P; Richman LK; Wilson JM
    Hum Gene Ther; 2018 Mar; 29(3):285-298. PubMed ID: 29378426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transduction Efficiency of Adeno-Associated Virus Serotypes After Local Injection in Mouse and Human Skeletal Muscle.
    Muraine L; Bensalah M; Dhiab J; Cordova G; Arandel L; Marhic A; Chapart M; Vasseur S; Benkhelifa-Ziyyat S; Bigot A; Butler-Browne G; Mouly V; Negroni E; Trollet C
    Hum Gene Ther; 2020 Feb; 31(3-4):233-240. PubMed ID: 31880951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus (AAV) vectors in cancer gene therapy.
    Santiago-Ortiz JL; Schaffer DV
    J Control Release; 2016 Oct; 240():287-301. PubMed ID: 26796040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection.
    Hammond SL; Leek AN; Richman EH; Tjalkens RB
    PLoS One; 2017; 12(12):e0188830. PubMed ID: 29244806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.